Purpose: Xp11.2 translocation renal cell carcinoma (RCC) is characterized by various translocations of the TFE3 transcription factor gene. These rare cancers occur predominantly in children and young adults. Here, we review the clinicopathological features of Xp11.2 translocation RCC.
INTRODUCTION
Renal cell carcinomas (RCCs) are heterogeneous tu mors that account for approximately 90% of all adult renal malig nancies. The most common subtypes are clear cell (60%-75%), papillary (10%-15%), chromophobe (5%), and collec ting duct carcinoma, and each is associated with uni que features at the molecular and genetic levels. Recent pro gress in under standing
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Xp11.2 translocation RCC
Organi za tion classifications list Xp11.2 translocation RCC as a distinct entity of renal tumor [4] .
Xp11.2 translocation RCC occurs predominantly in child ren and young adults; young adults account for 20% to 75% of pediatric RCC cases and about 1.5% of RCC adult cases [5, 6] . However, actual incidence largely remains underestimated. RCCs are def ined by several TFE3 translocations on chromosome Xp11.2, resulting in gene f usion between TFE3 and at least 6 possible partners. The most commonly observed translocations are t(X;17)(p11.2;q25), t(X;1)(p11.2;p34), and t(X;1)(p11.2;q21), which lead to gene fusions between TFE3 and ASPL, PSF, and PRCC, respectively [79] .
Xp11.2 translocation RCC typically demonstrates ne st ed or papillary architecture and is composed of cells with voluminous, clear, or eosinophilic cytoplasm that histologically mimic clear cell and papillary renal car cinoma [10, 11] . Translocations involving TFE3 induce protein overexpression and can be specifically identified on immunohistochemistry (IHC) by using an antibody for the Cterminal portion of TFE3, which has been reported in all fusion products. Nuclear labeling for TFE3 protein by IHC is specific to Xp11.2 translocation RCC, but cannot detect RCC in normal tissue or other tumor types. IHC analysis for nuclear TFE3 staining can confirm the diag nosis of Xp11 translocation RCC in archived tissues. A recently developed antibody for TFE3 protein is considered a highly sensitive (97.5%) and specific (99.6%) marker of these tumors [12] .
Previously published reports on Xp11.2 translocation RCC have documented the pathological and clinical fea tures of this rare form of renal carcinoma [9] . However, there are relatively few reported case studies in Korea [13] . Here, we report the clinicopathological features of Xp11.2 translocation RCC and oncologic outcomes in our institution.
MATERIALS AND METHODS
The study protocol was approved by the Institutional Review Board of the Asan Medical Center (20140498). The medical records of the Asan Medical Center, a tertiary referral cen ter, were screened for patients who had been patho logi cally diagnosed with Xp11. 2 Angiogenesis marker IHC analysis of the tumour tissue samples was performed by using the Ventana XT auto immunostainer (Roche, San Francisco, CA, USA) with the Optiview Dab Detection Kit (Roche) according to the manufacturer's instructions. IHC results were indepen dently evaluated by two specialized pathologists blind to the clinical data. A semiquantitative scoring system was used based on staining intensity (0, negative; 1, weak; 2, intermediate; 3, strong), which corresponds to the percentage of positivestained cells (0, <5% positive; 1, 5%-33.3% positive; 2, 33.3%-66.7% positive; 3, ≥66.7% positive). A score ≥1 indicates positive immunohistochemical iden tification of a marker. The Fuhrman nuclear grading sy stem, which uses a fourpoint multiparametric scale ba sed on nuclear features, size, shape, color, and nucleolar pro minence, was also used [14] . Tumor sizes were evaluated by measuring the largest diameter of the surgically removed mass.
RESULTS
The clinical characteristics of the patients are listed in Table 1 . The mean age at presentation was 43.4±20.0 years (range, 8-80 years), including 8 males and 13 females. Eleven of 21 patients were incidentally diagnosed. Five patients (33.3%) presented with flank pain, three patients 
Pinkish brown  --+  -+  -Unknown  12  Brown  -------13  Yellow  -------14  Pinkish yellow  --+  ---+  15  Yellow  -+  +  ----16  Golden yellow  --+  ----17 Golden yellow - Three patients underwent preoperative renal biopsy, but all three cases were misdiagnosed as clear cell RCC owing to the brown or yellow macroscopic appearance of the tumor. Under our care, three patients were misdiagno sed with clear cell RCC by preoperative renal biopsy (two patients were treated at another hospital). These biopsies often confirmed cystic change (31%), hemorrhage (43%), necrosis (25%), change to sarcomatoid (12.5%), calcification (12.5%), and lymphovascular invasion (12.5%) ( Table 2) . Micro scopically, the RCC tumor cells demonstrate an abu n dant and clear to eosinophilic cytoplasm and distinct cell borders that form the papillary architecture. The Fuhr man grade was 2 in 4 patients, 3 in 11 patients, and 4 in 3 patients.
All tumors demonstrated IHC staining for TFE3. IHC analysis of the surgically obtained tissue samples was per formed by using antibodies for tumor angiogenesis mar kers. Sixteen patients demonstrated strongly posi tive vascular endothelial growth factor (VEGF) staining inten sity, and one patient demonstrated weakly posi tive stai ning intensity. By IHC analysis, one patient demon strated strongly positive and one patient demon strated weakly positive VEGF receptor 2 (VEGFR2) staining. Two patients demonstrated strongly positive and eight patients demonstrated weakly positive plateletderived growth factorbeta (PDGFß) IHC staining. In addition, one patient demonstrated strong and one weak PDGF receptorbeta (PDGFRß) staining.
The pathological stage was T1a in five patients, T1b in seven patients, T2b in one patient, and T3a in five patients. On pathologic examination f or diagnosis, 11, 1, and 5 patients were diagnosed as stages I, II, or III RCC (including 4 patients with lymph node metastasis), respectively. Only four patients were diagnosed with distant metastasis (three pulmonary metastasis and one bone metastasis). At the time of this study, 15 patients had maintained a disease free status for a median duration of 30.0 months (range, 18-96.4 months). One patient was diagnosed with regional lymph node metastasis at 5 months postoperatively, but refused further treatment. Another patient developed bone metastasis at 4 months postoperatively. A female patient with bone metastasis received targeted sunitinib therapy for 4 months and everolimus for 2 months but died 14 months after treatment.
Another patient with distant metastasis (pulmonary metastasis) underwent preoperative renal biopsy but was misdiagnosed with clear cell RCC. He received targeted pazopanib therapy for 9 months before surgery (radical nephrectomy and lung bilobectomy). His disease progressed despite prior targeted therapy. After surgery, the patient received targeted temsirolimus therapy for 7 weeks but refused further treatment. The patient died 11.4 months after the operation.
Three patients diagnosed with Xp11 translocation RCC on kidney biopsy had a distant metastasis at the time of diagnosis. Two of these patients received targeted therapy. One patient with bone metastasis received targeted suniti nib therapy and radiation therapy; after that, disease status remained stable for 18 months. However, the disease pro gressed despite prior targeted therapy, and she received axitinib. The other patient with lung metastasis received temsirolimus for 5 weeks but died of cancer progression at 2 months.
DISCUSSION
Xp11.2 translocation RCC, a recently classified distinct subtype of RCC, is a rare tumor that usually affects child ren and adolescents; only a few adult cases have been repor ted to date [15, 16] . In our experience, Xp11.2 trans loca tion RCC accounts for 0.7% of all RCCs. In our insti tution, however, TFE3 stain is performed in young patients and in patients with histological features suggestive of trans location carcinoma. Xp11 translocation RCCs can also present with unusual morphology mimicking other types of RCCs, including multilocular cystic RCC-like features, pleomorphic giant cells, tubular growth reminiscent of collecting duct carcinoma, and welldeveloped fascicles of spindled neoplastic cells with bland nuclei and focal myxoid stroma [17] . Thus, the accuracy of diagnosis is variable. In the past, the incidence of Xp11.2 translocation RCC may have been underestimated.
The mean age of our current study population was 43.4 years, and the male:female ratio was 8:13. The mean tumor size in this series was 6.2 cm. Our cases demonstrated smaller tumor sizes than those reported in Patard's and Philippe's previous series (6.0-6.8 cm) and in the clinical experiences of Taipei Veterans General Hospital (9.2 cm). Also, our patients were older on average than in previous studies [18, 19] . The pT stage also differed in our series compared with previous studies: Xp11.2 translocation RCC diagnosis was more advanced (50% pT3/T4) in our series. Only five of our patients (33.3%) were diagnosed with pT3 stage, and pT4 (0%) has never been diagnosed in our hos pital [18, 19] . Lymph node and distal metastasis was diag nosed in 28.5% of our patients compared with 37.5% to 50% in other studies [18, 19] .
Morphologically, Xp11.2 translocation RCC is composed of cells with abundant clear or pale cytoplasm with nested or papillary architecture on routine hematoxylin and eo sinstained sections. This may overlap with clear cell RCC, such that three of our cases were misdiagnosed with clear cell RCC on preoperative renal biopsy. The incidence of Xp11.2 translocation RCC may be underestimated when diagnoses are made by using renal biopsies.
The most distinct immunochemical feature of Xp11.2 translocation RCCs is IHC TFE3 staining, which can pro vide a definitive diagnosis. A recently developed antibody for the TFE3 protein is a highly sensitive (97.5%) and spe cific (99.6%) marker of these tumors. In our current series, all 21 patients demonstrated IHC TFE3 staining.
In a recent study, TFE3 breakapart fluorescence in situ hybridization (FISH) was found to be useful for diag nosing Xp11.2 translocation RCC. In other studies, some patients were negative for immunohistochemical TFE3 staining but could be diagnosed on FISH, such that the incidence of Xp11.2 translocation RCC will change if FISH is used to diagnose this cancer [20, 21] .
Previous studies have not reported tumor angiogenesis markers in Xp11.2 translocation RCC. We tested for tumor angiogenesis markers. VEGF was strongly positive in 16 patients, whereas VEGFR2, PDGFß, and PDGFRß stained more weakly than VEGF (Table 3) . At the time of analysis, 15 of our patients were diseasefree for a median duration of 30.0 months. Four patients received targeted therapy, but only one patient with bone metastasis received tar geted sunitinib therapy and has been stable for 1 year. As a result, we treated metastatic Xp11.2 translocation RCC using targeted therapy, but almost all patients progressed and no targeted agent was effective. In a recent study, VEGFR2 expression was suggested to be a useful biomar ker for predicting the response to sunitinib in clear cell RCC [22] . Identif ying angiogenesis markers can be an important method for predicting response to targeted therapy in Xp11.2 translocation RCC. Further studies are needed to assess the relationship between targeted agents and angiogenesis markers.
The limitations in this study were the small number of patients analyzed, the retrospective design, the short duration, and the singlecenter setting.
CONCLUSIONS
In conclusion, we report here the clinical presentation, pathological features, and clinical outcomes of 21 recently diagnosed patients with Xp11.2 translocation RCC who were treated at our hospital. Xp11 translocation RCC tends to develop in young patients and shows lymph node meta stasis. Targeted therapy is not effective in our experi ence; surgical treatment is the only effective therapy for Xp11 translocation RCC. Further studies are needed to assess systemic therapies and longterm prognosis with regard to this cancer.
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